Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2000-07-11
2003-08-05
Achutamurthy, Ponnathapu (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C435S252300, C435S320100, C536S023500, C514S002600
Reexamination Certificate
active
06602984
ABSTRACT:
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is Human Elastase IV, sometimes hereinafter referred to as “HE IV”. The invention also relates to inhibiting the action of such polypeptides.
Elastase is a serine protease, capable of hydrolyzing the fibrous insoluble protein known as elastin. Elastin is a scleroprotein forming connective tissues, tendons, aortic integuments and cervical bundles of higher animals. Elastin is only slightly degraded by other proteases such as pepsin and trypsin.
During the course of study on arteriosclerosis, Balo, et al. observed degradation of the elastin fibers of arterial walls, and postulated the presence of a degrading enzyme (Schweiz, Z.,
Pathol. Bacteriol
., 12:350 (1949)). Subsequently, in 1952, Banga discovered an enzyme in the pancreas which specifically hydrolyses elastin. The enzyme was isolated in the form of crystals and named elastase (
Acta. Physiol. Acad. Sci. Hung
, 3:317 (1952).
Elastase has been confirmed to exist in the pancreas of most mammals, including humans, monkeys, cats, rabbits etc. A correlation is recognized between elastase activity in the age of a human being, a marked lowering in elastase activity in the pancreas and plasma of males over 40 and of females over 60 years has been reported by Loeven and Baldwin,
Gerontoloqia
, 17:170 (1971).
In the case of patients with arteriosclerosis, the elastase activity in the pancreas was reported by Balo and Banga to be markedly lower than that of healthy people, and in some cases it had completely disappeared (
Nature
, 178:310 (1956)). Subsequent studies have also demonstrated that elastase not only catalyses the hydrolysis of elastin but also accelerates elastin biosynthesis.
With the administration of porcine elastase to human beings, there is the risk of antibody formation due to the antigenic effect of the foreign protein. There is then the danger of anaphylaxis with repeated administration. Accordingly, human elastase is preferable for human use. However, it is extremely difficult to procure human elastase in sufficient quantities from the traditional source, the human pancreas.
SUMMARY OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a novel mature polypeptide which is HE IV, as well as fragments, analogs and derivatives thereof. The polypeptide of the present invention is of human origin.
In accordance with another aspect of the present invention, there are provided polynucleotides (DNA or RNA) which encode such polypeptides.
In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptide by recombinant techniques.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptide, or polynucleotide encoding such polypeptide for therapeutic purposes, for example, restoring arterial wall elasticity, reducing serum lipid levels and improving lipoprotein metabolism.
In accordance with yet a further aspect of the present invention, there is also provided nucleic acid probes comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.
In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.
In accordance with yet another aspect of the present invention, there are provided antagonists to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of in the treatment of inflammation, arthritis, e.g. rheumatoid arthritis and osteoarthritis, septic shock, pancreatitis and limit tissue damage in ulceration.
In accordance with still another aspect of the present invention, there are provided diagnostic assays for detecting diseases or susceptibility to diseases related to mutations in the nucleic acid sequences encoding a polypeptide of the present invention.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for in vitro purposes related to scientific research, for example, synthesis of DNA and manufacture of DNA vectors.
These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.
The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.
REFERENCES:
patent: 4968614 (1990-11-01), Takiguchi et al.
patent: 4985361 (1991-01-01), Takiguchi et al.
patent: 5710035 (1998-01-01), Greene et al.
patent: 5738991 (1998-04-01), Braxton et al.
patent: 5851814 (1998-12-01), Greene et al.
patent: 5856109 (1999-01-01), Braxton et al.
patent: 6030791 (2000-02-01), Braxton et al.
patent: 6107075 (2000-08-01), Greene et al.
patent: 0 198 645 (1990-11-01), None
patent: 0 157 604 (1992-12-01), None
patent: 0 768 378 (1997-04-01), None
patent: 61-111688 (1986-05-01), None
patent: 6-164898 (1994-06-01), None
patent: 7-074676 (1995-03-01), None
patent: 8-298990 (1996-11-01), None
patent: WO 96/00287 (1996-01-01), None
Largman et al., “Purification and characterization of two human pancreatic elastases,” Biochem. 15(11):2491-2500 (1976).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science 247:1306-1310 (1990).
Kang et al., “Identification of cDNAs encoding two novel rat pancreatic serine proteases,” Gene 110(2):181-187 (1992).
Tomomura et al., “Molecular cloning and expression of serum calcium-decreasing factor (caldecrin),” J. Biol. Chem. 270(51):30315-30321 (1995).
Tomomura et al., “Molecular cloning and expression of human caldecrin,” FEBS Letts. 386:26-28 (1996).
Yoshino-Yasuda et al., “Caldecrin is a novel-type serine protease expressed in pancreas, but its homologue, elastase IV, is an artifact during cloning derived from caldecrin gene,” J. Biochem. (Tokyo) 123:546-554 (1998).
Adams Mark D.
Greene John M.
Achutamurthy Ponnathapu
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Moore William W.
LandOfFree
Human elastase IV does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human elastase IV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human elastase IV will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3130186